Skip to main content
Year archive

Innate Pharma — 2009 filings

All 50 regulatory filings released by Innate Pharma (IPH) in 2009, sourced directly from the official regulator.

50 Filings
2009 Period
2009 filings (50)
Filing Released Lang
Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce son calendrier financier pour l’année 2010 et le règlement-livraison de son augmentation de capital
Report Publication Announcement
2009-12-23 French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces its financial and investor relations calendar for 2010 and the settlement and delivery of its capital increase
Report Publication Announcement
2009-12-23 English
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce aujourd’hui une levée de fonds d'un maximum de 24,3 millions d’euros réservée à catégories d’investisseurs
Capital/Financing Update
2009-12-18 French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces today a capital increase of a maximum of 24.3 million euros reserved to categories of investors
Share Issue/Capital Change
2009-12-18 English
Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce aujourd’hui l’ensemble des données présentées au 51ème congrès annuel de la société américaine d’hématologie (American Society of Hematol
Investor Presentation
2009-12-07 French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) provides today an overview of data presented during the 51st Annual Meeting of the American Society of Hematology (“ASH”)
AGM Information
2009-12-07 English
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces its turnover for the third quarter of 2009 and updates on its cash situation
Earnings Release 9M 2009
2009-11-06 English
Innate Pharma SA annonce son chiffre d’affaires trimestriel au 30 septembre 2009 et fait le point sur sa trésorerie
Earnings Release 9M 2009
2009-11-06 French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce avoir reçu l’autorisation de l’AFSSaPS pour l’extension de l’essai clinique de Phase I avec l'anticorps monoclonal IPH 2101 chez des patie
Regulatory Filings
2009-11-02 French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that it has received approval from AFSSaPS to start an extension of the Phase I clinical trial with its monoclonal antibody IPH 2101 in pat
Regulatory Filings
2009-11-02 English
Innate Pharma (Euronext Paris: FR0010331421 – IPH) reports Phase II clinical data with IPH 1101 in oncology
Earnings Release H1 2009
2009-09-21 English
Innate Pharma (Euronext Paris: FR0010331421 – IPH) présente des resultats cliniques de Phase II avec IPH 1101 en oncologie
Regulatory Filings
2009-09-21 French
L’Assemblée Générale d’Innate Pharma (Euronext Paris: FR0010331421 – IPH) a autorisé le Directoire à acheter des actions de la Société dans le cadre de la mise en œuvre d’un programme de rachat d’acti
AGM Information
2009-09-18 French
The General Meeting of Innate Pharma (Euronext Paris: FR0010331421 – IPH) has authorized the Executive Board to purchase its own shares through a share repurchase program.
Transaction in Own Shares
2009-09-18 English
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce aujourd’hui qu’à partir du 21 septembre 2009 la Société a confié à Natixis Securities la mise en œuvre d’un contrat de liquidité
Transaction in Own Shares
2009-09-18 French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces today the signature of a liquidity agreement with NatIxis Securities. The agreement will be effective September 21, 2009.
Capital/Financing Update
2009-09-18 English
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce sa participation au MidCap Event et la tenue d'une conférence téléphonique à 14h30 le lundi 21 à l’occasion de la publication à l’ESMO de
Regulatory Filings
2009-09-17 French
Innate Pharma announces that it will participate to the MidCap Event on 21-22 September, 2009. Furthermore, Innate will host a conference call on Monday 21, detailing interim clinical results for IPH
Regulatory Filings
2009-09-17 English
Inserm Transfert et Innate Pharma (Euronext : IPH) s’engagent dans un partenariat innovant pour le développement d’anticorps dans le cancer et les maladies inflammatoires et auto-immunes
Regulatory Filings
2009-09-11 French
Inserm Transfert and Innate Pharma (Euronext : IPH) enter into an innovative partnership for the development of new antibodies for the treatment of cancer and inflammatory or autoimmune diseases
Regulatory Filings
2009-09-11 English
Rapport financier semestriel au 30 juin 2009
Interim / Quarterly Report H1 2009
2009-09-04 French
Innate Pharma SA: Interim Financial Report June 30, 2009
Interim / Quarterly Report H1 2009
2009-09-04 English
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) annonce aujourd’hui ses résultats semestriels au 30 juin 2009
Interim / Quarterly Report H1 2009
2009-08-31 French
Innate Pharma SA (Euronext Paris: FR0010331421 – IPH) announces today its financial results for the first half of 2009
Interim / Quarterly Report H1 2009
2009-08-31 English
Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce l'initiation de la première étude de Phase II avec l’anticorps monoclonal IPH 2101, soutenue par un nouveau financement d’Oséo de 2,9 mil
Capital/Financing Update
2009-08-27 French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces today the start of the first Phase II clinical trial with monoclonal antibody IPH 2101 supported by a new 2.9 million euros financing from
Capital/Financing Update
2009-08-27 English
Innate Pharma SA (Euronext Paris : FR0010331421 – IPH) annonce les résultats de son assemblée générale mixte ainsi que des changements dans la composition de son Conseil de Surveillance
AGM Information
2009-06-23 French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces today the outcome of its annual general meeting, including changes in the composition of its Supervisory Board
AGM Information
2009-06-23 English
Innate Pharma SA et ses partenaires annoncent le démarrage opérationnel de PLATINE, plateforme commune d’immunomonitoring
Regulatory Filings
2009-06-15 French
Innate Pharma SA and its partners announced the operational start of PLATINE, a joint immuno-monitoring platform
Regulatory Filings
2009-06-15 English
Innate Pharma (Euronext Paris : FR0010331421 – IPH) annonce la tenue de son assemblée générale annuelle le 23 juin prochain à 11 heures au siège social de la Société, à Marseille.
AGM Information
2009-06-05 French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders on June 23, 2009, in its headquarters, in Marseilles, France.
AGM Information
2009-06-05 English
Innate Pharma (Euronext Paris : FR0010331421 – IPH) présente des résultats préliminaires pour deux essais de Phase I avec IPH 2101 (anticorps « anti-KIR » ) au congrès de l’American Society of Clinica
Earnings Release Q2 2009
2009-05-29 French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) reports today preliminary results for two Phase I trials with IPH 2101 (“anti-KIR” ) at the 2009 American Society of Clinical Oncology (“ASCO”) Meeti
Earnings Release Q1 2009
2009-05-29 English
Innate Pharma SA : Rapport annuel et Document de Référence 2008
Report Publication Announcement
2009-05-06 French
Innate Pharma SA: 2008 Reference Document and Annual Report
Report Publication Announcement
2009-05-06 English
Innate Pharma (Euronext Paris : FR0010331421 – IPH) annonce son chiffre d'affaires trimestriel au 31 mars et fait le point sur sa trésorerie
Earnings Release Q1 2009
2009-05-05 French
Innate Pharma S.A. (Euronext Paris: FR0010331421 – IPH) announces its turnover for the first quarter of 2009 and updates on its cash situation
Earnings Release Q1 2009
2009-05-05 English
Innate Pharma SA annonce le renforcement de son équipe de management avec la nomination du Docteur Marcel Rozencweig au poste de Senior Vice Président chargé de la stratégie clinique et réglementaire
Board/Management Information
2009-04-27 French
Innate Pharma SA announces today the strengthening of its management team with the appointment of Marcel Rozencweig, MD, as Senior Vice President in charge of clinical and regulatory strategy
Board/Management Information
2009-04-27 English
Innate Pharma (Euronext Paris : FR0010331421 – IPH) annonce sa participation prochaine à BioCapital Europe, C,F&B Smallcap Event et BioEquity Europe
Report Publication Announcement
2009-04-17 French
Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces it will participate to the following analyst and investor conferences in the coming weeks: BioCapital Europe, C,F&B Smallcap Event and BioE
Report Publication Announcement
2009-04-17 English
Innate Pharma SA (la « Société »), société biopharmaceutique spécialisée dans le développement de médicaments immuno-thérapeutiques innovants pour le traitement du cancer et d’autres maladies graves,
Annual Report FY 2008
2009-02-27 French
Innate Pharma S.A. (the “Company”), a clinical stage biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and other severe diseases, reports today its financial results f
Earnings Release FY 2008
2009-02-27 English
Innate Pharma annonce l’atteinte d’un paiement d’étape pré-clinique pour un nouveau projet d’anticorps monoclonal développé en collaboration avec Novo Nordisk A/S
Regulatory Filings
2009-02-12 French
Innate Pharma announces the achievement of a milestone payment in a new monoclonal antibody project developed in collaboration with Novo Nordisk A/S
Regulatory Filings
2009-02-12 English
Innate Pharma SA, société biopharmaceutique qui développe des candidat-médicaments ciblant le système immunitaire inné, annonce des produits opérationnels de 12,9 millions d’euros pour 2008.
Earnings Release FY 2008
2009-02-06 French
Innate Pharma SA, a biopharmaceutical company developing first-in-class drug candidates targeting the innate immune system, today announces an operating revenue of 12.9 million Euros for the year 2008
Earnings Release FY 2008
2009-02-06 English
Vivalis et Innate Pharma annoncent aujourd’hui la signature d’un accord de collaboration et de licence commerciale pour le développement d’un nouvel anticorps d’Innate Pharma sur la plateforme EB66® p
Regulatory Filings
2009-01-21 French
Vivalis and Innate Pharma sign a collaboration and commercial license agreement to develop Innate’s novel monoclonal antibody, to be manufactured with Vivalis’ EB66® platform, for rare cutaneous cance
Capital/Financing Update
2009-01-21 English